Phase 1 BIO 300 Oral Suspension
Phase 1
Recruiting
- Conditions
- Healthy Volunteer Study
- Interventions
- Drug: BIO 300 Oral Suspension
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 56
- Registration Number
- NCT06741345
- Locations
- πΊπΈ
Nucleus Network, LLC, Saint Paul, Minnesota, United States
BIO 300 Oral Powder Safety and Pharmacokinetics
Phase 1
Completed
- Conditions
- Acute Radiation Syndrome
- Interventions
- Drug: BIO 300 Oral Powder
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 34
- Registration Number
- NCT04650555
- Locations
- πΊπΈ
Nucleus Network, Ltd (Formally Prism Research, LLC), Saint Paul, Minnesota, United States
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
Phase 2
Active, not recruiting
- Conditions
- Long COVIDCOVID-19Post-acute Respiratory Complications of COVID-19Pulmonary Fibrosis
- Interventions
- Drug: BIO 300 Oral SuspensionDrug: Placebo
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT04482595
- Locations
- πΊπΈ
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
πΊπΈNYU Langone Health, New York, New York, United States
πΊπΈUniversity of Texas Health Science Center at Houston, Houston, Texas, United States
BIO 300 Non-Small Cell Lung Cancer Study
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT02567799
- Locations
- πΊπΈ
University of Maryland School of Medicine, Baltimore, Maryland, United States
πΊπΈHenry Ford Hospital, Detroit, Michigan, United States
πΊπΈMedical College of Wisconsin, Milwaukee, Wisconsin, United States
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
Phase 2
Completed
- Conditions
- DementiaAlzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT01928420
- Locations
- πΊπΈ
James J Peters Veterans Affairs Medical Center, Bronx, New York, United States
7-Keto DHEA for the Treatment of PTSD
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT01861847
- Locations
- πΊπΈ
Bay Pines VA Healthcare System, Bay Pines, Florida, United States
Safety and Pharmacokinetic Study of BIO 300 Capsules
Phase 1
Completed
- Conditions
- Acute Radiation Syndrome
- Interventions
- Drug: BIO 300 Capsules
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT00504335
Β© Copyright 2025. All Rights Reserved by MedPath